High prevalence of skin cancer to foster the growth of the actinic keratosis market

 

The term "actinic keratosis" refers to a group of skin conditions, characterized by hyperpigmentation, hyper-pigmentation, or skin changes. This disease is caused by a buildup of a pigment called melanin in the epidermis. Melanin protects the skin from UV light and from infections. However, some types of skin overproduce melanin, which can lead to the development of actinic keratosis. There are several different conditions that can cause actinic keratosis. Skin disease, exposure to UV radiation, trauma, and certain drugs can also cause the condition.

The growing prevalence of actinic keratosis is a prime factor contributing to the growth of the actinic keratosis market. According to The Skin Cancer Foundation, 1 in 5 Americans will develop skin cancer by the age of 70. Actinic keratosis is the most common precancer; it affects more than 58 million Americans. It is one of the precancerous skin lesions diseases. Increasing awareness regarding the disease due to the growing number of campaigns that focus on raising awareness regarding the disease. The development of healthcare infrastructure especially across emerging economies due to increasing investment is also fostering the growth of the actinic keratosis market.

North America is projected to gain significant growth over the forecast period and this is attributed to the increasing cancer treatment spending in order to improve the treatment efficacy. According to the National Cancer Institute, Estimated national expenditures for cancer care in the United States in 2018 were $150.8 billion. In future years, costs are likely to increase as the population ages and more people have cancer. This is also attributed to the high prevalence of skin cancer in the region.

Key Developments:

In December 2020, Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis. Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp
In March 2020, Almirall applies for European approval for a new actinic keratosis option. The European Medicines Agency will review submission from dermatology specialist Almirall (ALM: MC) to market tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis
In December 2017, Almirall, S.A (ALM), a global skin-health-focused pharmaceutical company announced an agreement with Athenex, Inc. for the treatment of cancer and related conditions, to further develop and commercialize KX2-391 for the treatment of actinic keratosis and other skin conditions.